Followers | 9842 |
Posts | 260026 |
Boards Moderated | 4 |
Alias Born | 12/27/2006 |
Friday, May 15, 2020 4:34:27 PM
Link to Video - click here to watch the technical chart video
Recent ALDX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 10:07:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 09:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:06:48 AM
- Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap • Business Wire • 08/08/2024 11:00:00 AM
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap • Business Wire • 08/07/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/01/2024 09:01:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:11:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:03:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 11:01:40 AM
- Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable • Business Wire • 06/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 11:01:34 AM
- Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease • Business Wire • 06/13/2024 11:00:00 AM
- Aldeyra Therapeutics to Host Investor Roundtable Q&A • Business Wire • 06/12/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:07:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:09 PM
- Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease • Business Wire • 05/08/2024 11:00:00 AM
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day • Business Wire • 04/25/2024 11:00:00 AM
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 • Business Wire • 04/18/2024 11:00:00 AM
- Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease • Business Wire • 03/28/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/07/2024 09:54:33 PM
FEATURED Element79 Gold Corp Provides Update on Nevada Portfolio • Aug 23, 2024 8:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM